CA2137799A1 - Methodes therapeutique et diagnostique fondee sur l'expression de la neurotropine-4 - Google Patents

Methodes therapeutique et diagnostique fondee sur l'expression de la neurotropine-4

Info

Publication number
CA2137799A1
CA2137799A1 CA002137799A CA2137799A CA2137799A1 CA 2137799 A1 CA2137799 A1 CA 2137799A1 CA 002137799 A CA002137799 A CA 002137799A CA 2137799 A CA2137799 A CA 2137799A CA 2137799 A1 CA2137799 A1 CA 2137799A1
Authority
CA
Canada
Prior art keywords
seq
ngf
arg
ser
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002137799A
Other languages
English (en)
Inventor
Nancy Ip
Charles A. Altar
Peter Distefano
Roseann Ventimiglia
Stanley Wiegand
Vivian Wong
George D. Yancopoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2137799A1 publication Critical patent/CA2137799A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
CA002137799A 1992-06-12 1993-06-11 Methodes therapeutique et diagnostique fondee sur l'expression de la neurotropine-4 Abandoned CA2137799A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89819492A 1992-06-12 1992-06-12
US898,194 1992-06-12

Publications (1)

Publication Number Publication Date
CA2137799A1 true CA2137799A1 (fr) 1993-12-23

Family

ID=25409081

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002137799A Abandoned CA2137799A1 (fr) 1992-06-12 1993-06-11 Methodes therapeutique et diagnostique fondee sur l'expression de la neurotropine-4

Country Status (6)

Country Link
EP (1) EP0644937A4 (fr)
JP (1) JPH07509600A (fr)
AU (1) AU4535993A (fr)
CA (1) CA2137799A1 (fr)
IL (1) IL106037A0 (fr)
WO (1) WO1993025684A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE140966T1 (de) * 1990-09-25 1996-08-15 Genentech Inc Neuer neurotropischer faktor
US6506728B2 (en) 1990-09-25 2003-01-14 Genentech, Inc. Methods using a novel neurotrophic factor, NT-4
US6566091B1 (en) 1990-09-25 2003-05-20 Genentech, Inc. Neurotrophic factor
US5470719A (en) * 1994-03-18 1995-11-28 Meng; Shi-Yuan Modified OmpA signal sequence for enhanced secretion of polypeptides
EP0753013A1 (fr) * 1994-03-29 1997-01-15 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Neurotrophine-6: un nouveau membre de la famille des neurotrophines
US7144983B1 (en) 1997-02-03 2006-12-05 Genentech, Inc. Pantropic neurotrophic factors
US5728803A (en) * 1994-06-03 1998-03-17 Genentech, Inc. Pantropic neurotrophic factors
US5556837A (en) * 1994-08-01 1996-09-17 Regeneron Pharmaceuticals Inc. Methods for treating addictive disorders
CN1233963A (zh) * 1996-09-13 1999-11-03 有限会社最先端医学研究所 神经营养因子的眼科用组合物、视神经机能障碍治疗药和视神经机能障碍治疗方法
EP1010432A4 (fr) 1997-01-23 2004-03-10 Sumitomo Pharma Remedes contre le diabete
US6331523B1 (en) 1998-03-12 2001-12-18 Genentech, Inc. Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5
AU8559398A (en) * 1998-08-05 2000-02-28 Advanced Medicine Research Institute Remedies for cerebral central lesions with the use of neurotrophic factors
WO2003011395A2 (fr) 2001-07-31 2003-02-13 University Of Medicine & Dentistry Of New Jersey Methode d'utilisation de neurotrophines servant a manipuler la capacite de reproduction
AU2006310882A1 (en) * 2005-11-07 2007-05-10 Copenhagen University Neurotrophin-derived peptide sequences
KR20090091181A (ko) * 2006-12-20 2009-08-26 리나트 뉴로사이언스 코퍼레이션 자가면역 장애의 치료를 위한 티로신 수용체 키나아제 ｂ 작용제
CN111000984A (zh) * 2019-11-16 2020-04-14 祁展楷 一组蛇神经生长因子及蛇神经生长因子前体在治疗老年痴呆上的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1000980B (el) * 1989-08-30 1993-03-31 Max Planck Gesellschaft Νευροτροφινη-3,ενας νεος neυροτροφικος παραγοντας που σχετιζεται με τον παραγοντα αναπτυξης νευρων και τον νευροτροφικο παραγοντα που προερχεται απο τον εγκεφαλο.
ATE140966T1 (de) * 1990-09-25 1996-08-15 Genentech Inc Neuer neurotropischer faktor
IL101661A (en) * 1991-04-23 1998-02-08 Regeneron Pharma Method for detecting, identifying or measuring agents having neurotrophin activity
WO1992020797A1 (fr) * 1991-05-20 1992-11-26 Case Western Reserve University Facteur neurotrophique, sa preparation et ses utilisations
WO1992020365A1 (fr) * 1991-05-21 1992-11-26 Regeneron Pharmaceuticals, Inc. Procedes therapeutiques et diagnostiques basees sur l'expression de neurotrophine-4
RU94016525A (ru) * 1991-07-10 1996-06-10 Ридженерон Фармасьютикалз Способы лечения заболеваний двигательных нейронов

Also Published As

Publication number Publication date
WO1993025684A1 (fr) 1993-12-23
EP0644937A1 (fr) 1995-03-29
JPH07509600A (ja) 1995-10-26
AU4535993A (en) 1994-01-04
IL106037A0 (en) 1994-08-26
EP0644937A4 (en) 1995-05-03

Similar Documents

Publication Publication Date Title
FI117556B (fi) Yhdistelmä-DNA-menetelmä hermoston tukikudosperäisen neurotrofisen tekijän tuottamiseksi
CA2040437C (fr) Neurotrophine-3, nouveau facteur neurotrophique lie au facteur de croissance du tissu nerveux et au facteur neurotrophique derive du cerveau
CA2137799A1 (fr) Methodes therapeutique et diagnostique fondee sur l'expression de la neurotropine-4
AU714107B2 (en) Neurturin and related growth factors
US5221620A (en) Cloning and expression of transforming growth factor β2
CA2088990A1 (fr) Facteurs neurotrophiques chimeriques
JP2002514043A (ja) 内胚葉、心臓、および神経の誘導因子
WO1997021811A2 (fr) Nouveaux recepteurs du type tyrosine kinase et ligands
PT92603B (pt) Processo de producao de factor de crescimento transformante, quimerico,beta
US6852838B2 (en) Tyrosine kinase receptors and ligands
AU758011B2 (en) Persephin and related growth factors
AU674659B2 (en) Therapeutic and diagnostic methods based on neurotrophin-4 expression
US6933276B1 (en) Methods of treating peripheral neuropathies using neurotrophin-3
NZ270485A (en) Diagnosis of motor neuron disease using neurotrophin-4 (nt-4) and methods for measuring its activity
US20020128440A1 (en) Endoderm, cardiac and neural inducing factors - oligonucleotides for expressing human frazzled (frzb-1) protein

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 19990611